These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34315570)

  • 21. Multisite measurement of regional oxygen saturation in Fontan patients with and without protein-losing enteropathy at rest and during exercise.
    Schröer S; Fahlbusch FB; Münch F; Alkassar M; Toka HR; Rauh M; Rüffer A; Cesnjevar R; Dittrich S; Toka O; Moosmann J
    Pediatr Res; 2019 May; 85(6):777-785. PubMed ID: 30795005
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early Impact of Fontan Operation on Enteric Protein Loss.
    Patel JK; Loomes KM; Goldberg DJ; Mercer-Rosa L; Dodds K; Rychik J
    Ann Thorac Surg; 2016 Mar; 101(3):1025-30. PubMed ID: 26652137
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Use of Fecal Calprotectin Levels in the Fontan population.
    Miranda C; Taqatqa A; Chapa-Rodriguez A; Holton JP; Awad SM
    Pediatr Cardiol; 2018 Mar; 39(3):591-594. PubMed ID: 29282492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protein-Losing Enteropathy and Plastic Bronchitis After the Fontan Operation.
    Peyton C
    Crit Care Nurse; 2018 Dec; 38(6):e5-e12. PubMed ID: 30504504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein-losing enteropathy recurrence after pediatric heart transplantation: Multicenter case series.
    Sagray E; Johnson JN; Schumacher KR; West S; Lowery RE; Simpson K
    Pediatr Transplant; 2022 Aug; 26(5):e14295. PubMed ID: 35451219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical outcomes and improved survival in patients with protein-losing enteropathy after the Fontan operation.
    John AS; Johnson JA; Khan M; Driscoll DJ; Warnes CA; Cetta F
    J Am Coll Cardiol; 2014 Jul; 64(1):54-62. PubMed ID: 24998129
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral budesonide treatment for protein-losing enteropathy in Fontan-palliated patients.
    Schumacher KR; Cools M; Goldstein BH; Ioffe-Dahan V; King K; Gaffney D; Russell MW
    Pediatr Cardiol; 2011 Oct; 32(7):966-71. PubMed ID: 21660539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sympathetic and vascular dysfunction in adult patients with Fontan circulation.
    Lambert E; d'Udekem Y; Cheung M; Sari CI; Inman J; Ahimastos A; Eikelis N; Pathak A; King I; Grigg L; Schlaich M; Lambert G
    Int J Cardiol; 2013 Aug; 167(4):1333-8. PubMed ID: 22525342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dopamine as a potential rescue therapy for refractory protein-losing enteropathy in Fontan-palliated patients.
    Friedland-Little JM; Gajarski RJ; Schumacher KR
    Pediatr Transplant; 2017 Jun; 21(4):. PubMed ID: 28370952
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are children with protein-losing enteropathy after the Fontan operation at increased risk of cytomegalovirus enteropathy? A report of two cases.
    Bauer C; Tulzer G
    Cardiol Young; 2020 Mar; 30(3):431-432. PubMed ID: 31973780
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The use of oral budesonide in adolescents and adults with protein-losing enteropathy after the Fontan operation.
    John AS; Driscoll DJ; Warnes CA; Phillips SD; Cetta F
    Ann Thorac Surg; 2011 Oct; 92(4):1451-6. PubMed ID: 21784410
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protein-losing enteropathy after the Fontan operation: clinical analysis of nine cases.
    Lin WS; Hwang MS; Chung HT; Chu JJ; Lai MW; Yang JS; Huang SC; Huang JL; Su WJ
    Chang Gung Med J; 2006; 29(5):505-12. PubMed ID: 17214396
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pathophysiology and complications of Fontan circulation.
    Mazza GA; Gribaudo E; Agnoletti G
    Acta Biomed; 2021 Nov; 92(5):e2021260. PubMed ID: 34738582
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Successful childbirth in a Fontan with protein losing enteropathy.
    Ryan KN; Leonardi MR; Hasselman TE
    Cardiol Young; 2019 Apr; 29(4):547-548. PubMed ID: 30968802
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fenestration of extracardiac fontan and reversal of protein-losing enteropathy: case report.
    Lemes V; Murphy AM; Osterman FA; Laschinger JC; Kan JS
    Pediatr Cardiol; 1998; 19(4):355-7. PubMed ID: 9636262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risk Factors and Clinical Significance of Lymphopenia in Survivors of the Fontan Procedure for Single-Ventricle Congenital Cardiac Disease.
    Morsheimer MM; Rychik J; Forbes L; Dodds K; Goldberg DJ; Sullivan K; Heimall JR
    J Allergy Clin Immunol Pract; 2016; 4(3):491-6. PubMed ID: 26897303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Failure of the fontan circulation.
    Gewillig M; Goldberg DJ
    Heart Fail Clin; 2014 Jan; 10(1):105-16. PubMed ID: 24275298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current Treatment Options for the Failing Fontan Circulation.
    Driesen BW; Voskuil M; Grotenhuis HB
    Curr Cardiol Rev; 2022; 18(4):e060122200067. PubMed ID: 34994331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent exacerbations of protein-losing enteropathy after initiation of growth hormone therapy in a Fontan patient controlled with spironolactone.
    Grattan MJ; McCrindle BW
    Congenit Heart Dis; 2010; 5(2):165-7. PubMed ID: 20412490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fontan-Associated Dyslipidemia.
    Lubert AM; Alsaied T; Palermo JJ; Anwar N; Urbina EM; Brown NM; Alexander C; Almeneisi H; Wu F; Leventhal AR; Aldweib N; Mendelson M; Opotowsky AR
    J Am Heart Assoc; 2021 Apr; 10(7):e019578. PubMed ID: 33787283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.